Merkel Cell Carcinoma: Epidemiology, Immunotherapy Response, and Staging

Clinical Overview

Merkel cell carcinoma (MCC) is a rare but aggressive neuroendocrine skin cancer arising from mechanoreceptor Merkel cells in the basal layer of the epidermis. MCC accounts for <1% of all skin cancers (~3,000 new cases annually in the United States) but accounts for disproportionately high mortality, with 5-year overall survival of only 50-60% despite multimodal treatment. The disease is characterized by rapid growth, high propensity for regional and distant metastases, and poor prognosis compared to other skin cancers. However, discovery of the Merkel cell polyomavirus (MCPyV) in 2008 and subsequent development of effective immunotherapy have substantially improved outcomes for appropriately treated patients. Early detection and aggressive multimodal treatment including surgery, sentinel lymph node biopsy, and adjuvant immunotherapy are essential for optimizing outcomes.

Epidemiology & Risk Factors

MCC typically affects elderly patients (median age 65-75 years) with fair skin. Unlike melanoma and SCC, there is no strong gender predominance. Ultraviolet radiation exposure is a risk factor but appears less critical than in other skin cancers. Merkel cell polyomavirus (MCPyV) is found in approximately 80% of MCC tumors and is thought to play a critical etiologic role. MCPyV is ubiquitous in the general population (~50-80% seropositive), but malignant transformation occurs rarely, suggesting additional cofactors are necessary. Immunocompromised individuals (particularly HIV-positive patients and transplant recipients) have 10-40 times higher incidence. Other risk factors include: chronic sun exposure, fair skin phototype, advanced age, and possibly arsenic exposure. Geographic variation is notable: incidence is highest in Australia and highest-latitude United States (Minnesota, Vermont). The remarkable improvement in MCC outcomes since 2015 (when pembrolizumab was approved) underscores the immunogenic nature of the disease and high sensitivity to immunotherapy.

Pathophysiology

MCC arises through neuroendocrine differentiation of transformed keratinocytes. Merkel cell polyomavirus (MCPyV) is detected in 75-95% of cases and encodes T antigens that interfere with p53 and retinoblastoma (Rb) tumor suppressor pathways. MCPyV-positive MCCs typically have fewer somatic mutations than MCPyV-negative MCCs; viral T antigen provides the primary transforming stimulus. MCPyV-negative MCCs (5-25% of cases) frequently harbor TP53 and RB mutations, indicating loss of tumor suppressor function through alternative mechanisms. Histologically, MCC is composed of small round cells with scant cytoplasm, salt-and-pepper chromatin, and high mitotic rate. Neuroendocrine differentiation is evident on electron microscopy with abundant neurosecretory granules. Immunohistochemistry reveals positivity for neuroendocrine markers (chromogranin A, synaptophysin) and cytokeratin 20 (CK20). MCPyV T antigen can be detected with monoclonal antibodies (CM2B4) in MCPyV-positive cases. The extraordinary sensitivity of MCC to immunotherapy (pembrolizumab and avelumab response rates 60-80%) reflects high tumor mutational burden and abundant tumor-infiltrating lymphocytes, suggesting potent immunogenicity.

Clinical Presentation & Classification

MCC typically presents as a rapidly enlarging firm nodule or plaque on sun-exposed skin (face, neck, extremities). The lesion is often erythematous, flesh-colored, or violaceous. Size ranges from <1cm to several centimeters; lesions grow rapidly (weeks to months), distinguishing MCC from slower-growing melanoma or SCC. The lesion may ulcerate or bleed. Notably, MCC frequently metastasizes to regional lymph nodes before the primary tumor is clinically apparent; approximately 50% of patients present with regional nodal metastases at diagnosis. Occasionally, the patient presents with enlarged lymph nodes discovered on imaging or physical examination, prompting investigation that reveals a small or occult primary MCC. Distant metastases to liver, lung, bone, or brain may be present at diagnosis in 10-15% of patients. The rapid clinical course and propensity for early metastasis underscore the aggressive nature of MCC and justify prompt diagnosis and treatment.

Diagnosis & Staging

Clinical diagnosis is challenging; MCC should be in the differential for any rapidly growing erythematous or violaceous nodule on the face or extremities of an elderly patient. Biopsy (punch or excisional) confirms diagnosis. Histopathology shows small round cells with scant cytoplasm arranged in sheets or nests; the tumor is typically located in the dermis with possible extension into subcutaneous tissue. Immunohistochemistry is essential for diagnosis: CK20 (cytokeratin 20) is positive in ~90% of cases with characteristic perinuclear dotted pattern (in contrast to CK20 positivity in Merkel cells of normal skin). Synaptophysin and chromogranin A are typically positive. CDX2 and TTF-1 are usually negative (helpful for excluding metastatic small cell lung cancer or neuroendocrine carcinoma of other origins). MCPyV status should be determined (monoclonal antibody CM2B4) or MCPyV DNA PCR performed. TNM staging (8th edition AJCC) incorporates: primary tumor size (<2cm vs. ≥2cm), Clark level, mitotic rate, and presence of regional/distant metastases. Stage I is localized tumor <2cm without nodal involvement (excellent prognosis with 5-year OS >85% with adjuvant therapy). Stage II is localized tumor ≥2cm or any size with adverse histologic features. Stage III is regional nodal metastases (either clinically occult on SLN biopsy or clinically evident). Stage IIIA is clinically occult SLN metastases; Stage IIIB is clinically evident nodal disease. Stage IV is distant metastases. Patients with primary MCC should undergo: complete surgical staging with SLN biopsy (detects occult nodal disease in 25-30% of clinically node-negative patients), baseline imaging (CT chest/abdomen/pelvis or MRI, brain MRI if symptoms suggest CNS involvement), and laboratory studies.

Treatment Algorithm

Complete surgical excision of the primary tumor with 1-2cm margins is the initial treatment. Wide local excision of the primary MCC is performed, with histopathologically confirmed clear margins. SLN biopsy is recommended for all patients with localized MCC to accurately stage and identify occult nodal metastases. If SLN is positive, completion lymph node dissection of the involved basin is performed. For localized Stage I-II disease treated with surgery and SLN biopsy, adjuvant immunotherapy is strongly recommended: pembrolizumab 200mg IV every 3 weeks for up to 1 year (KEYNOTE-076 trial) or avelumab 10mg/kg IV every 2 weeks for up to 1 year (JAVELIN Merkel 100 trial) both significantly improved recurrence-free survival compared to observation. Pembrolizumab improves 2-year RFS from 50% to 75%; avelumab improves RFS comparably. For clinically node-positive disease (Stage IIIB), adjuvant radiation therapy (typically 5000-6000 cGy in standard fractionation) is recommended in addition to chemotherapy or immunotherapy to improve local control. For metastatic disease (Stage IV), first-line systemic therapy is immunotherapy: pembrolizumab or avelumab (response rates 60-75%, median PFS 9-12 months). Combination chemotherapy (cisplatin-based) is less commonly used upfront but may be considered for immunotherapy-refractory disease. For MCPyV-positive disease, recent interest in MCPyV-directed therapies (therapeutic vaccines, adoptive T cell therapy) is growing, though these remain largely investigational.

Prognosis & Survival

MCC prognosis has improved dramatically since introduction of adjuvant immunotherapy. Stage I (localized <2cm, no nodal involvement) has 5-year overall survival of 85-95% with adjuvant immunotherapy, compared to 60-70% with surgery alone. Stage II (localized ≥2cm) has 5-year OS of 70-80% with adjuvant immunotherapy. Stage IIIA (clinically occult SLN metastases) has 5-year OS of 60-70% with surgery, adjuvant RT if needed, and immunotherapy. Stage IIIB (clinically evident nodal disease) has 5-year OS of 40-50% with multimodal therapy including adjuvant RT and immunotherapy. Stage IV (distant metastases) has median OS of 12-18 months with immunotherapy, compared to 6-8 months with chemotherapy. Factors improving prognosis include: small tumor size (<2cm), absence of nodal involvement at presentation, MCPyV-positive status (paradoxically associated with better immunotherapy response), and response to immunotherapy. Patients with durable immunotherapy response (complete or partial response lasting >6 months) have substantially better long-term survival (median OS >60 months in some series).

When to See a Dermatologist

Any rapidly growing erythematous or violaceous nodule on the face or extremities warrants prompt dermatologic evaluation and biopsy. Given the aggressive nature of MCC and high propensity for regional nodal involvement at diagnosis, early detection is critical. Patients with diagnosed MCC require oncologic evaluation for staging imaging and treatment planning. Follow-up surveillance for MCC typically includes: clinical examination every 3 months for the first 2 years (when most recurrences occur), then every 6 months for years 2-5. Imaging (ultrasound of regional nodes, CT chest/abdomen/pelvis, brain MRI) is performed based on clinical concern for recurrence. Patients on adjuvant immunotherapy require regular clinic visits and laboratory monitoring for immune-related adverse events.

Frequently Asked Questions

I have Merkel cell carcinoma. Will it spread to my lymph nodes?

Approximately 50% of patients have regional lymph node involvement at or shortly after diagnosis of MCC. Sentinel lymph node biopsy is performed to detect occult nodal metastases in 25-30% of clinically node-negative patients. Once regional metastases develop, the risk of subsequent distant metastases increases substantially. This is why complete surgical staging with SLN biopsy and adjuvant immunotherapy are critical components of treatment.

What is Merkel cell polyomavirus, and does it matter if my cancer is positive or negative?

Merkel cell polyomavirus (MCPyV) is found in 75-95% of MCC tumors and is thought to play an etiologic role. Paradoxically, MCPyV-positive MCCs often have better prognosis and higher response rates to immunotherapy than MCPyV-negative MCCs. From a treatment standpoint, whether your MCC is MCPyV-positive or negative does not currently change management (both receive the same immunotherapy); however, MCPyV status may help predict prognosis and guide future targeted therapies under development.

What is my survival outlook if I have Stage III Merkel cell carcinoma with one positive lymph node?

Stage IIIA MCC (clinically occult SLN metastasis in one node) has 5-year overall survival of 60-70% with complete surgical treatment (excision of primary plus completion nodal dissection) and adjuvant immunotherapy (pembrolizumab or avelumab for 1 year). Without adjuvant immunotherapy, outcomes are worse (40-50% 5-year OS). Regular surveillance is essential because recurrence risk is significant; most recurrences occur within the first 2 years.

I'm 82 years old with Merkel cell carcinoma. Am I too old for immunotherapy?

Age alone is not a contraindication to immunotherapy. Multiple clinical trials of adjuvant pembrolizumab and avelumab for MCC included elderly patients (median ages in trials were 65-70 years with substantial numbers >80 years old). Fitness for treatment is assessed individually based on functional status, comorbidities, and performance status rather than chronologic age. Your oncologist will discuss whether you are a candidate for immunotherapy based on your individual situation.

References

Last updated: March 2026. This article reflects current evidence-based clinical practice and is intended for healthcare professionals and informed patients. Always consult with a board-certified dermatologist for personalized medical advice.